We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
National Cancer Institute (NCI)-designated centers are marking up oncology drugs by as much as 633 percent over the acquisition cost, according to a new cost analysis. Read More
GlaxoSmithKline is buying Sierra Oncology and its investigational cancer drug momelotinib in a $1.9 billion windfall for the San Mateo, Calif.- based biopharmaceutical company. Read More